Study on CD44 as a Cancer Stem Cell Marker for Head and Neck Squamous Cell Carcinoma

CD44, a hyaluronic acid cell-surface glycoprotein receptor, has been linked to tumour growth and progression, as well as being used as a Cancer Stem Cell (CSC) marker in head and neck squamous cell carcinoma (HNSCC). CD44’s prognostic usefulness, on the other hand, is still unknown. As a result, the goal of this study was to determine the role of CD44 in HNSCC by quantifying soluble CD44 levels and correlating them with HNSCC prognosis and treatment. Patients with HNSCC (n=40) and age-matched healthy volunteers (n=30) were randomly selected as cases and controls, respectively. All of the participants provided demographic and health-related information. ELISA was used to determine the levels of sCD44 in the blood of patients and controls. In HNSCC cases, CD44 expression was substantially higher than in healthy people. CD44 expression was shown to be considerably lower in HNSCC cases during and after treatment. CD44 appears to be a critical marker for HNSCC stem cell identification. It is easily detectable in serum and hence has the potential to be utilised as a diagnostic marker. More research could show its potential as a diagnostic and prognostic marker, as well as a therapeutic target.

Author (S) Details

Kereena Chukka
Department of Biotechnology, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur, AP, India.

B. Sailaja
Department of General Medicine, Government General Hospital/Guntur Medical College, Guntur, AP, India.

D. S. Raju Naidu
Department of Radiotherapy, Guntur Medical College/ Govt. General Hospital, Guntur, AP, India.

Subramanyam Dasari
School of Medicine, Indiana University, Bloomington, IN- 47405, USA.

Vishnuvardhan Zakkula
Department of Botany & Microbiology, Acharya Nagarjuna University, Guntur, A.P, India.

Gnaneswar Atturu
Department of Vascular and Endovascular Surgery, CARE Hospitals, Hyderabad, India.

View Book :-

Leave a Reply

Your email address will not be published. Required fields are marked *